查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1995395

乳房切片市場：2026-2032年全球市場預測（依產品類型、手術類型、導引方法、切片檢查部位、最終用戶及臨床適應症分類）

Breast Biopsy Market by Product Type, Procedure Type, Guidance Modality, Biopsy Site, End User, Clinical Indication - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年乳房切片市場價值 19 億美元，預計到 2025 年將成長至 20.2 億美元，複合年成長率為 6.63%，到 2032 年將達到 31.7 億美元。

主要市場統計數據
基準年 2024 19億美元
預計年份：2025年 20.2億美元
預測年份：2032年 31.7億美元
複合年成長率 (%) 6.63%

我們將建立一個以患者為中心的乳房切片護理綜合框架，將臨床結果、醫療設備創新和醫療機構策略連結起來。

乳房疾病的診斷過程依賴於及時、準確且微創的組織取樣。成像技術和醫療設備工程的進步為臨床醫生提供了更多樣化的切片檢查選擇，但隨著患者對安全性和舒適度的期望不斷提高，手術流程的優先順序也在改變。因此，醫療機構的決策者、製造商和臨床團隊必須權衡日益成長的準確性需求與不同醫療環境的營運限制。

成像技術的進步、醫療設備的模組化以及以病人為中心的服務模式，是如何重塑乳房切片護理的臨床工作流程和採購重點的？

乳房切片領域正經歷著一場變革，其驅動力包括技術小型化、成像技術的整合以及對以患者為中心的工作流程的重新重視。高解析度超音波和先進的磁振造影序列等影像方法變得更加普及和互通性，使臨床醫生能夠更準確地識別病灶並縮短手術時間。同時，醫療設備製造商正致力於模組化設計，優先考慮人體工學、即時回饋以及與多種影像平台的兼容性。

評估 2025 年價格調整對下游營運和供應鏈的影響，並檢視相關人員的採購策略。

改變醫療設備採購和臨床報銷經濟計算方式的政策可能會對整個供應鏈和醫療服務系統產生連鎖反應。 2025年實施的關稅調整帶來了明顯的成本壓力，影響了採購決策、定價策略和庫存管理的地理佈局。為此，採購團隊重新評估了供應商多樣性，最佳化了物流，並實施了合約保障措施，以降低跨境關稅波動帶來的風險。

透過對醫療設備技術、手術類型和最終用戶環境進行詳細的細分分析，可以製定有針對性的商業化和臨床引入策略。

細分市場洞察揭示了不同技術、手術類型和終端使用者環境之間存在的細微需求差異，因此需要差異化的商業性和臨床策略。在技​​術領域，核心針穿刺活體組織切片設備佔據了手術選擇的大部分，提供全自動和半自動配置，兼顧了處理能力和操作者控制。細針穿刺切片穿刺針包括具有增強超音波影像清晰度的迴聲增強型，以及在細胞學主導流程中仍發揮重要作用的標準針。真空輔助系統包含兩類產品：一類是專為臨床環境便利性而最佳化的手持式設備，另一類是專為複雜病變和高容量環境而設計的桌上型平台。

影響北美、歐洲、中東和非洲以及亞太地區產品引進、分銷和臨床支援優先事項的區域趨勢和策略考量。

區域趨勢影響臨床實踐模式和商業性需求，而從地理角度出發的細緻觀點有助於相關人員優先考慮市場准入、分銷和支援方面的投資。在美洲，醫療保健系統強調以價值為導向的醫療服務、提高手術效率和擴大門診服務，這推動了對使用者友善設備和整合工作流程解決方案的需求。該地區的報銷機制和醫院採購流程往往優先考慮可證實的臨床效益和完善的售後支援。

競爭格局和企業級策略訊號凸顯了透過整合解決方案、臨床夥伴關係和卓越服務實現差異化的重要性。

乳房切片生態系統的競爭動態以技術差異化、服務主導的價值提案和策略聯盟為特徵。領先的醫療設備開發商正日益將數位化工具和硬體產品結合，以改善手術規劃、文件記錄和術後追蹤。因此，能夠提供涵蓋設備可靠性、影像互通性和資料整合等端到端解決方案的公司，在與醫療機構建立長期合作關係方面具有優勢。

為製造商和醫療保健機構提供實用策略指南，以協調創新、賦能和價值鏈韌性，從而加速採用和價值實現。

行業領導企業應採取平衡的策略，將產品創新與營運支援和臨床醫生能力提升相結合，以加速產品普及並保持價值。首先，優先考慮降低設定複雜性、同時提升操作流程人體工學和影像相容性的設備設計。這種方法可以縮短掌握時間並提高處理能力。其次，投資於臨床醫生教育計畫和基於模擬的培訓，以加強技術一致性並支持品質指標。第三，拓展服務範圍，使其超越硬體本身，涵蓋流程諮詢、遠端故障排除和結果追蹤工具，進而加強客戶關係。

透過文獻整合、臨床醫生訪談和資料三角驗證，我們採用穩健且多方面的調查方法來檢驗策略見解並減輕分析限制。

本研究採用結構化且透明的調查方法，整合了相關證據，旨在確保分析的嚴謹性和實際應用價值。研究首先對同儕審查的臨床文獻、監管申報文件和醫療設備技術文件進行全面審查，以建立對安全性概況、手術適應症和器械特性的基礎性理解。隨後，透過對介入放射科醫生、乳房外科醫生、採購經理和器械工程師的訪談，進行了一項定性初步調查，以確定實際應用中的促進因素、障礙和尚未解決的需求。

整合策略挑戰，展示臨床證據、商業化敏捷性和營運韌性如何決定乳房切片護理的長期成功。

一項整合臨床趨勢、技術進步和營運實際情況的分析凸顯了短期挑戰，其中準確性、患者體驗和供應鏈韌性是決定成敗的關鍵因素。如果醫療設備在目標準確性、人體工學和與影像系統的互通性方面有顯著改進，並且配備完善的培訓和服務基礎設施，則很可能被臨床應用所接受。同時，醫療系統將繼續優先考慮檢測能力和成本控制，從而催生對可在門診和住院環境中實施的模組化解決方案的需求。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：乳房切片市場：依產品類型分類

  • 切片穿刺針
  • 導航系統
  • 癌症切片檢查
  • 耗材和配件

第9章：乳房切片市場：依手術類型分類

  • 核心針穿刺切片
  • 穿刺切片檢查
  • 細針穿刺切片檢查
  • 手術/開放式切片檢查
    • 切除切片檢查
    • 切片檢查

第10章：乳房切片市場：依引導法分類

  • 超音波引導下切片檢查
  • 立體定位X光引導切片檢查
  • 磁振造影引導切片檢查

第11章乳房切片市場：依切片檢查部位分類

  • 乳腺實質
  • 腋窩和區域淋巴結
  • 乳頭導管結構

第12章：乳房切片市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 專科診所

第13章：乳房切片市場：依臨床適應症分類

  • 早期癌症篩檢
  • 治療方法方案
  • 監測復發情形及治療進展

第14章乳房切片市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：乳房切片市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章乳房切片市場：按國家/地區分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國乳房切片市場

第18章：中國乳房切片市場

第19章 競爭情勢

  • 2024年市場集中度分析
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2024 年
  • 2024年產品系列分析
  • 基準分析，2024 年
  • Argon Medical Devices, Inc.
  • Becton Dickinson and Company
  • Cook Group Incorporated
  • Danaher Corporation
  • Exact Sciences Corporation
  • FUJIFILM Corporation
  • GE HealthCare
  • Hologic, Inc.
  • Medtronic PLC
  • Merit Medical Systems, Inc.
  • Siemens Healthineers AG
  • Sysmex Corporation
Product Code: MRR-4F4C36263235

The Breast Biopsy Market was valued at USD 1.90 billion in 2024 and is projected to grow to USD 2.02 billion in 2025, with a CAGR of 6.63%, reaching USD 3.17 billion by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.90 billion
Estimated Year [2025] USD 2.02 billion
Forecast Year [2032] USD 3.17 billion
CAGR (%) 6.63%

Setting the stage for an integrated and patient-centered view of breast biopsy care that connects clinical outcomes, device innovation, and institutional strategy

The diagnostic pathway for breast disease hinges on timely, accurate, and minimally invasive tissue sampling. Advances in imaging and device engineering have diversified the array of biopsy options available to clinicians, while patient expectations for safety and comfort have shifted procedural priorities. Consequently, institutional decision-makers, manufacturers, and clinical teams must reconcile rising demand for precision with operational constraints in multiple care settings.

This introduction establishes the context for deeper analysis by outlining the evolving intersections of technology, clinical practice, and health system delivery. It highlights the growing emphasis on procedure personalization, cross-disciplinary collaboration, and data-driven quality assurance. Moreover, it underscores how regulatory emphasis on device safety and comparative effectiveness is reshaping product development cycles and adoption pathways. By framing the topic in terms of clinical outcomes, throughput, and patient experience, the subsequent sections will explore the strategic implications for stakeholders across the value chain.

How converging imaging advances, device modularity, and patient-centered delivery models are reshaping clinical workflows and procurement priorities in breast biopsy care

The landscape for breast biopsy is undergoing transformative shifts driven by technological miniaturization, imaging convergence, and a renewed focus on patient-centric workflows. Imaging modalities such as high-resolution ultrasound and advanced MRI sequences have become more accessible and interoperable, enabling clinicians to target lesions with greater accuracy and reduced procedure time. At the same time, device manufacturers have converged on modular designs that prioritize ergonomics, real-time feedback, and compatibility with multiple imaging platforms.

These shifts are also reflected in care delivery models: outpatient and ambulatory environments increasingly perform diagnostically complex procedures previously restricted to inpatient settings, driven by efficiency and patient convenience. Meanwhile, clinical pathways emphasize shared decision-making, which requires clearer communication of biopsy risks, benefits, and expected diagnostic value. Taken together, these trends are rewriting procurement priorities, operator training requirements, and vendor collaborations, creating new opportunities and competitive pressures for stakeholders prepared to adapt.

Assessing the downstream operational and supply chain consequences of tariff adjustments during 2025 and how stakeholders realigned sourcing and procurement strategies

Policy instruments that alter the economic calculus of device procurement and clinical reimbursement can produce ripple effects throughout the supply chain and care continuum. Tariff adjustments implemented in 2025 introduced discrete cost pressures that influenced sourcing decisions, pricing strategies, and the geographic orientation of inventory management. Procurement teams responded by reassessing supplier diversity, optimizing logistics, and seeking contractual protections that mitigate exposure to cross-border tariff volatility.

In parallel, manufacturers evaluated their manufacturing footprints and aftermarket support models to preserve margin and ensure continuity of supply. Regulatory compliance and quality assurance remained top priorities during these adjustments, prompting incremental investments in domestic assembly and validated distribution channels. Clinicians and health system leaders adapted by reexamining case mix and scheduling patterns to absorb incremental unit costs without compromising access. Ultimately, the tariff environment underscored the importance of flexible sourcing strategies and proactive commercial planning to sustain service levels amid shifting trade conditions.

Detailed segmentation analysis across device technologies, procedural modalities, and end-user settings to inform targeted commercialization and clinical adoption strategies

Segmentation insights reveal nuanced demand drivers that vary across technology, procedure type, and end-user settings and therefore require differentiated commercial and clinical strategies. Within technology, Core Needle Biopsy Devices account for a substantial portion of procedural choices and are available in automated and semi-automated configurations that balance throughput with operator control. Fine Needle Aspiration Needles include echo-enhanced variants for improved sonographic visualization alongside standard needles that remain relevant for cytology-driven workflows. Vacuum-Assisted Systems present a bifurcated product set with handheld devices optimized for point-of-care convenience and table-configured platforms designed for complex lesion access and high-volume environments.

Procedure-type segmentation further informs device selection and training priorities. MRI-guided approaches are differentiated by closed-bore and open-bore systems, each aligning with specific lesion visibility and patient tolerance considerations. Palpation-guided procedures persist as pragmatic options through freehand palpation and grid-guided techniques where imaging access is limited. Stereotactic biopsies comprise prone and upright configurations, which influence patient positioning, imaging geometry, and procedure time. Ultrasound-guided interventions vary between 2D and emerging 3D imaging capabilities, which affect targeting precision and operator learning curves. Finally, end-user segmentation clarifies where demand concentrates and how procurement and operational criteria diverge: Ambulatory Surgery Centers, including diagnostic centers and outpatient surgery centers, prioritize throughput and per-procedure cost-efficiency; Hospitals, spanning private and public institutions, emphasize comprehensive service portfolios and robust inventory support; Specialty Clinics, such as oncology and radiology clinics, focus on clinical specialization, integrated diagnostics, and patient navigation. Together, these segmentation lenses illuminate where innovation, service models, and commercial engagement will have the highest strategic impact.

Regional dynamics and strategic considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence adoption, distribution, and clinical support priorities

Regional dynamics shape both clinical practice patterns and commercial imperatives, and a geographically nuanced view helps stakeholders prioritize market entry, distribution, and support investments. In the Americas, health systems emphasize value-based care, procedural efficiency, and outpatient expansion, creating demand for user-friendly devices and integrated workflow solutions. Reimbursement mechanisms and hospital procurement processes in this region tend to favor demonstrable clinical benefit and robust post-market support.

In Europe, Middle East & Africa, diverse regulatory regimes and heterogeneous infrastructure create a mosaic of opportunity and constraint. Some markets in this region adopt advanced imaging and device platforms rapidly, while others prioritize cost-effective, scalable solutions that can be deployed across variable care settings. Local manufacturing, regulatory harmonization, and training partnerships often become differentiators. Asia-Pacific presents a broad spectrum of adoption trajectories where rapid hospital modernization and rising screening programs drive demand for precision biopsy solutions; meanwhile, market entrants must navigate local regulatory pathways, distribution networks, and clinician training needs to realize sustainable uptake. Understanding these regional contours allows manufacturers and health system planners to tailor product portfolios, commercial models, and support services for maximal clinical and operational relevance.

Competitive landscape and company-level strategic signals highlighting differentiation through integrated solutions, clinical partnerships, and service excellence

Competitive dynamics in the breast biopsy ecosystem are characterized by technology differentiation, service-led value propositions, and strategic collaboration. Leading device developers increasingly couple hardware offerings with digital tools that enhance procedural planning, documentation, and post-procedure tracking. As a result, companies that can demonstrate end-to-end solutions-combining device reliability, imaging interoperability, and data integration-are better positioned to secure long-term institutional relationships.

Partnerships between device manufacturers, imaging vendors, and clinical centers accelerate innovation cycles and support the development of clinically validated workflows. Moreover, supply chain resilience, regulatory responsiveness, and service excellence serve as critical decision criteria for hospital systems and specialty clinics. New entrants tend to focus on niche innovations-such as ergonomic designs or disposable components-to gain initial traction, while established players leverage scale, global distribution networks, and clinical evidence to defend market positions. Ultimately, the competitive landscape rewards organizations that invest in clinician training, post-market surveillance, and meaningful outcome-based evidence.

Actionable strategic playbook for manufacturers and health systems to align innovation, enablement, and supply chain resilience to accelerate adoption and value realization

Industry leaders should pursue a balanced strategy that aligns product innovation with operational support and clinician enablement to accelerate adoption and sustain value. First, prioritize device designs that enhance procedural ergonomics and imaging compatibility while reducing setup complexity; this approach shortens learning curves and improves throughput. Second, invest in clinician education programs and simulation-based training that reinforce technique consistency and support quality metrics. Third, expand service offerings beyond hardware to include procedural workflow consulting, remote troubleshooting, and outcome-tracking tools that create stickier customer relationships.

Furthermore, diversify supply chain options to mitigate tariff and logistics-related disruptions by combining localized assembly with strategic inventory hubs. Forge partnerships with imaging vendors and specialty clinics to validate integrated workflows and produce real-world evidence that resonates with payers and procurement committees. Lastly, adopt flexible commercial models-ranging from per-procedure consumable pricing to bundled solution contracts-to accommodate diverse customer budgets and accelerate adoption across ambulatory, hospital, and specialty settings. These combined actions will help organizations translate innovation into measurable clinical and commercial gains.

Robust, multi-source research methodology combining literature synthesis, clinician interviews, and data triangulation to validate strategic insights and mitigate analytical limitations

This research synthesizes evidence from a structured and transparent methodology designed to ensure analytical rigor and practical relevance. The approach began with a comprehensive review of peer-reviewed clinical literature, regulatory filings, and technical device documentation to establish a baseline understanding of safety profiles, procedural indications, and device characteristics. Next, qualitative primary research included interviews with practicing interventional radiologists, breast surgeons, procurement leaders, and device engineers to surface real-world adoption drivers, barriers, and unmet needs.

Data triangulation ensured consistency between primary insights and secondary sources, and validation workshops with clinical advisors refined interpretations and prioritized strategic implications. Analytical methods included comparative device feature mapping, procedural pathway analysis, and supply chain risk assessment. The research also documents methodological limitations, such as variability in practice patterns across regions and the evolving nature of imaging technology, and describes mitigation strategies like purposive sampling of experts and sensitivity checks. Ethical considerations governed confidentiality, informed consent for all interviews, and anonymization of practitioner-level data to preserve professional privacy.

Synthesis of strategic imperatives showing how clinical evidence, commercialization agility, and operational resilience will determine long-term success in breast biopsy care

The synthesis of clinical trends, technological progress, and operational realities points to a near-term agenda where precision, patient experience, and supply chain resilience intersect as primary determinants of success. Devices that offer clear improvements in targeting accuracy, ergonomics, and interoperability with imaging systems will find receptive clinical audiences when supported by robust training and service commitments. Meanwhile, health systems will continue to emphasize procedural throughput and cost control, creating demand for modular solutions that can be deployed across ambulatory and hospital settings.

In summary, stakeholders that integrate clinical evidence generation, flexible commercial models, and resilient supply strategies will be best positioned to capture value and improve patient outcomes. As the landscape evolves, continuous engagement with clinicians, proactive investment in post-market evidence, and adaptive commercial planning will remain essential to sustaining momentum and translating innovation into routine practice.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2024
  • 3.5. FPNV Positioning Matrix, 2024
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Breast Biopsy Market, by Product Type

  • 8.1. Biopsy Needles
  • 8.2. Guidance Systems
  • 8.3. Biopsy Guns
  • 8.4. Consumables & Accessories

9. Breast Biopsy Market, by Procedure Type

  • 9.1. Core Needle Biopsy
  • 9.2. Vacuum-Assisted Biopsy
  • 9.3. Fine Needle Aspiration Biopsy
  • 9.4. Surgical/Open Biopsy
    • 9.4.1. Excisional Biopsy
    • 9.4.2. Incisional Biopsy

10. Breast Biopsy Market, by Guidance Modality

  • 10.1. Ultrasound-Guided Biopsy
  • 10.2. Stereotactic X-Ray-Guided Biopsy
  • 10.3. MRI-Guided Biopsy

11. Breast Biopsy Market, by Biopsy Site

  • 11.1. Breast Parenchyma
  • 11.2. Axillary & Regional Lymph Nodes
  • 11.3. Nipple & Ductal Structures

12. Breast Biopsy Market, by End User

  • 12.1. Ambulatory Surgery Centers
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Breast Biopsy Market, by Clinical Indication

  • 13.1. Early Cancer Screening
  • 13.2. Therapy Selection
  • 13.3. Recurrence & Treatment Monitoring

14. Breast Biopsy Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Breast Biopsy Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Breast Biopsy Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Breast Biopsy Market

18. China Breast Biopsy Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2024
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2024
  • 19.3. Product Portfolio Analysis, 2024
  • 19.4. Benchmarking Analysis, 2024
  • 19.5. Argon Medical Devices, Inc.
  • 19.6. Becton Dickinson and Company
  • 19.7. Cook Group Incorporated
  • 19.8. Danaher Corporation
  • 19.9. Exact Sciences Corporation
  • 19.10. FUJIFILM Corporation
  • 19.11. GE HealthCare
  • 19.12. Hologic, Inc.
  • 19.13. Medtronic PLC
  • 19.14. Merit Medical Systems, Inc.
  • 19.15. Siemens Healthineers AG
  • 19.16. Sysmex Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL BREAST BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BREAST BIOPSY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 3. GLOBAL BREAST BIOPSY MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 4. GLOBAL BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BREAST BIOPSY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BREAST BIOPSY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BREAST BIOPSY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES BREAST BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA BREAST BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BREAST BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BREAST BIOPSY MARKET SIZE, BY BIOPSY NEEDLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BREAST BIOPSY MARKET SIZE, BY BIOPSY NEEDLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BREAST BIOPSY MARKET SIZE, BY BIOPSY NEEDLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BREAST BIOPSY MARKET SIZE, BY GUIDANCE SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BREAST BIOPSY MARKET SIZE, BY GUIDANCE SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BREAST BIOPSY MARKET SIZE, BY GUIDANCE SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BREAST BIOPSY MARKET SIZE, BY BIOPSY GUNS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BREAST BIOPSY MARKET SIZE, BY BIOPSY GUNS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BREAST BIOPSY MARKET SIZE, BY BIOPSY GUNS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BREAST BIOPSY MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BREAST BIOPSY MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BREAST BIOPSY MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BREAST BIOPSY MARKET SIZE, BY VACUUM-ASSISTED BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BREAST BIOPSY MARKET SIZE, BY VACUUM-ASSISTED BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BREAST BIOPSY MARKET SIZE, BY VACUUM-ASSISTED BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BREAST BIOPSY MARKET SIZE, BY FINE NEEDLE ASPIRATION BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BREAST BIOPSY MARKET SIZE, BY FINE NEEDLE ASPIRATION BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BREAST BIOPSY MARKET SIZE, BY FINE NEEDLE ASPIRATION BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BREAST BIOPSY MARKET SIZE, BY EXCISIONAL BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BREAST BIOPSY MARKET SIZE, BY EXCISIONAL BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BREAST BIOPSY MARKET SIZE, BY EXCISIONAL BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BREAST BIOPSY MARKET SIZE, BY INCISIONAL BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BREAST BIOPSY MARKET SIZE, BY INCISIONAL BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BREAST BIOPSY MARKET SIZE, BY INCISIONAL BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BREAST BIOPSY MARKET SIZE, BY ULTRASOUND-GUIDED BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BREAST BIOPSY MARKET SIZE, BY ULTRASOUND-GUIDED BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BREAST BIOPSY MARKET SIZE, BY ULTRASOUND-GUIDED BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BREAST BIOPSY MARKET SIZE, BY STEREOTACTIC X-RAY-GUIDED BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BREAST BIOPSY MARKET SIZE, BY STEREOTACTIC X-RAY-GUIDED BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BREAST BIOPSY MARKET SIZE, BY STEREOTACTIC X-RAY-GUIDED BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BREAST BIOPSY MARKET SIZE, BY MRI-GUIDED BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BREAST BIOPSY MARKET SIZE, BY MRI-GUIDED BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BREAST BIOPSY MARKET SIZE, BY MRI-GUIDED BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BREAST BIOPSY MARKET SIZE, BY BREAST PARENCHYMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BREAST BIOPSY MARKET SIZE, BY BREAST PARENCHYMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BREAST BIOPSY MARKET SIZE, BY BREAST PARENCHYMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BREAST BIOPSY MARKET SIZE, BY AXILLARY & REGIONAL LYMPH NODES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BREAST BIOPSY MARKET SIZE, BY AXILLARY & REGIONAL LYMPH NODES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BREAST BIOPSY MARKET SIZE, BY AXILLARY & REGIONAL LYMPH NODES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BREAST BIOPSY MARKET SIZE, BY NIPPLE & DUCTAL STRUCTURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BREAST BIOPSY MARKET SIZE, BY NIPPLE & DUCTAL STRUCTURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BREAST BIOPSY MARKET SIZE, BY NIPPLE & DUCTAL STRUCTURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BREAST BIOPSY MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BREAST BIOPSY MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BREAST BIOPSY MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BREAST BIOPSY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BREAST BIOPSY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BREAST BIOPSY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BREAST BIOPSY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BREAST BIOPSY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BREAST BIOPSY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BREAST BIOPSY MARKET SIZE, BY EARLY CANCER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BREAST BIOPSY MARKET SIZE, BY EARLY CANCER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BREAST BIOPSY MARKET SIZE, BY EARLY CANCER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BREAST BIOPSY MARKET SIZE, BY THERAPY SELECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BREAST BIOPSY MARKET SIZE, BY THERAPY SELECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BREAST BIOPSY MARKET SIZE, BY THERAPY SELECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BREAST BIOPSY MARKET SIZE, BY RECURRENCE & TREATMENT MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BREAST BIOPSY MARKET SIZE, BY RECURRENCE & TREATMENT MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BREAST BIOPSY MARKET SIZE, BY RECURRENCE & TREATMENT MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BREAST BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS BREAST BIOPSY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA BREAST BIOPSY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL BREAST BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 149. GCC BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GCC BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. GCC BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. GCC BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 153. GCC BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 154. GCC BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 155. GCC BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. GCC BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 173. G7 BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. G7 BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. G7 BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. G7 BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 177. G7 BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 178. G7 BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 179. G7 BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. G7 BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 181. NATO BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. NATO BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. NATO BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. NATO BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 185. NATO BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 186. NATO BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 187. NATO BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. NATO BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES BREAST BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA BREAST BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)